Editorial: Challenges of COVID-19 in dermatology patients on immunosuppression: Risk, outcome, vaccination, and beyond
Front Med (Lausanne)
.
2022 Aug 9:9:987534.
doi: 10.3389/fmed.2022.987534.
eCollection 2022.
Authors
Hamidreza Mahmoudi
1
,
Aikaterini Patsatsi
2
,
Dedee F Murrell
3
,
Soheil Tavakolpour
4
,
Maryam Daneshpazhooh
1
Affiliations
1
Autoimmune Bullous Diseases Research Center, Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
2
Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
3
Department of Dermatology, St George Hospital, University of New South Wales, Sydney, NSW, Australia.
4
Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.
PMID:
36017004
PMCID:
PMC9396300
DOI:
10.3389/fmed.2022.987534
No abstract available
Keywords:
COVID-19; SARS-CoV-2; autoimmune bullous diseases; melanoma; psoriasis; vaccination.
Publication types
Editorial